Why the Emyria (ASX:EMD) share price is climbing 7% higher today

The Emyria Ltd (ASX: EMD) share price is climbing following a positive announcement to service its growing demand. We take a closer look.

| More on:
Five stacked building blocks with green arrows, indicating rising inflation or share prices

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Emyria Ltd (ASX: EMD) share price is climbing higher following the announcement of an additional clinic to its portfolio. During mid-morning trade, healthcare technology and services company's shares are up 5.13% to 21 cents.

Emyria responds to growing demand

The Emyria share price is on the rise after providing investors with a positive update to respond to its growing demand.

According to its release, Emyria advised that it has expanded its subsidiary, Emerald Clinics, with the addition of a second consulting suite. Located in Perth, Western Australia, the new clinic will seek to service to the strong demand. Just last month, the company witnessed record patient appointments nationally, which it opened its second Melbourne office in response.

Additionally, the Perth office will have four consulting rooms located within the site of the West Leederville Private Hospital building. The new suite is expected to improve patient access to Emerald Clinics and help support the company's future EMD-003 clinical trials.

Currently, EMD-003 —Emyria's first cannabinoid-based medicine to reduce symptoms of anxiety, depression and stress — is in the planning phase. The company is hoping to achieve registration with the Australian Therapeutic Goods Administration (TGA) sometime this calendar year.

What did the managing director say?

Emyria managing director, Dr. Michael Winlo, touched on a number of the points. He said:

Western Australia was the first Emerald Clinics location. Demand for our services from both patients and referring doctors has grown every month since we opened. We anticipate this expansion will allow us to improve our waiting times and see more patients which, in turn, improves our proprietary data asset (Emyria Data).

Insights from Emyria Data is now informing the design and planning of pivotal drug registration clinical trials for our first drug program, EMD-003 – a cannabinoid medicine targeting unmet needs in mental health.

The additional clinical capacity in Perth also allows us to support a wider range of clinical trials in different indications as well as help us deliver on the recently awarded Future Health Research and Innovation Grant involving our TGA-registered remote monitoring system.

Emyria share price review

The Emyria share price has been a solid performer for the last 12 months, rising over 100%. Year-to-date, however, has seen the company's share recorded a 110% gain, reflecting fresh positive investor sentiment. It's worth noting that in February, its shares reached an all-time high of 27 cents.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A cute little kid in a suit pulls a shocked face as he talks on his smartphone.
Share Market News

Telstra share price hits 8-year high amid a lacklustre trading week

The ASX 200 communications services sector was the best performer last week, rising 2.96%.

Read more »

share buyers, investors, happy investors
ETFs

How I would build a $100,000 portfolio with ASX ETFs today

You don't need more than three ETFs to build a diversified portfolio...

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to 100%

Analysts are expecting these shares to deliver big returns over the next 12 months.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »